References
1. Ferastraoaru D, Bax HJ, Bergmann C, et al. AllergoOncology: Ultra-low
IgE, a potential novel biomarker in cancer - A Position Paper of the
European Academy of Allergy and Clinical Immunology (EAACI). Clin
Transl Allergy . 2020;10(1):1-16. doi:10.1186/s13601-020-00335-w
2. Busse W, Buhl R, Fernandez Vidaurre C, et al. Omalizumab and the risk
of malignancy: Results from a pooled analysis. J Allergy Clin
Immunol . 2012;129(4):983-989.e6. doi:10.1016/j.jaci.2012.01.033
3. Long A, Rahmaoui A, Rothman KJ, et al. Incidence of malignancy in
patients with moderate-to-severe asthma treated with or without
omalizumab. J Allergy Clin Immunol . 2014;134(3).
doi:10.1016/j.jaci.2014.02.007
4. Faillie JL. Caseānon-case studies: Principle, methods, bias and
interpretation. Therapie . 2019;74(2):225-232.
doi:10.1016/j.therap.2019.01.006
5. Montastruc JL, Sommet A, Bagheri H, Lapeyre-Mestre M. Benefits and
strengths of the disproportionality analysis for identification of
adverse drug reactions in a pharmacovigilance database. Br J Clin
Pharmacol . 2011;72(6):905-908. doi:10.1111/j.1365-2125.2011.04037.x
6. Faillie JL, Petit P, Montastruc JL, Hillaire-Buys D. Scientific
evidence and controversies about pioglitazone and bladder cancer: Which
lessons can be drawn? Drug Saf . 2013;36(9):693-707.
doi:10.1007/s40264-013-0086-y